COSELA®（Trilaciclib Hydrochloride for Injection ）：2 posters
Antitumor Activity and Safety Profile of Trilaciclib in Chinese patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) receiving Chemotherapy (TRACES): Updated results from TRACES
Presentation Number：1998P
Speakers ：Ying Liu (Changchun, China)
Onsite Poster display date： Saturday, 21 October 2023
1998P.pdf
Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: a review on the basis of clinical trials
Presentation Number：2024P
Speakers： Manuel Dómine (Madrid, Spain)
Onsite Poster display date：Saturday, 21 October 2023
Envafolimab （subcutaneously injectable PD-L1 antibody）：5 posters
Phase Ib/II Trial of Envafolimab, a Novel Subcutaneous Single‑domain Anti‑PD‑L1 Monoclonal Antibody, Plus Lenvatinib in Patients with Selected Advanced Solid Tumors
Presentation Number：1049P
Speakers：Tianshu Liu (Shanghai, China)
Onsite Poster display date：Monday, 23 October 2023
1049P.pdf
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial
Presentation Number：920P
Speakers ：Xiaohui Wang (Guangzhou, China)
Onsite Poster display date：Sunday, 22 October 2023
920P.pdf
Combination Therapy of Envafolimab and Suvemcitug in Patients with Hepatocellular Carcinoma (HCC): Results from a Phase II Clinical Trial
Presentation Number：959P
Speakers：Lixia Ma (Changchun, China)
Onsite Poster display date：Monday, 23 October 2023
959P.pdf
Combination Therapy of Envafolimab, Suvemcitug, and FOLFIRI in Patients with Metastatic Microsatellite Stable (MSS) or Mismatch-repair Proficient (pMMR) Colorectal Cancer: Results from a Phase II Clinical Trial
Presentation Number：636P
Speakers：Ying Liu (ChangChun, China)
Onsite Poster display date：Sunday, 22 October 2023
636P.pdf
Combination Therapy of Envafolimab and Suvemcitug with chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): Results from a Phase II Clinical Trial
Presentation Number：1467P
Speakers ：Chunjiao Wu (Changchun, China)
Onsite Poster display date：Monday, 23 October 2023
1467P.pdf
Endostar®（Recombinant Human Endostatin）：1 poster
Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presentation Number：1545P
Speakers：Yuexiao Qi (Lanzhou, China)
Onsite Poster display date：Monday, 23 October 2023
Suvemcitug（VEGF mAb）：3 posters
Combination Therapy of Envafolimab and Suvemcitug in Patients with Hepatocellular Carcinoma (HCC): Results from a Phase II Clinical Trial
Presentation Number：959P
Speakers：Lixia Ma (Changchun, China)
Onsite Poster display date：Monday, 23 October 2023
959P.pdf
Combination Therapy of Envafolimab, Suvemcitug, and FOLFIRI in Patients with Metastatic Microsatellite Stable (MSS) or Mismatch-repair Proficient (pMMR) Colorectal Cancer: Results from a Phase II Clinical Trial
Presentation Number：636P
Speakers：Ying Liu (Changchun, China)
Onsite Poster display date：Sunday, 22 October 2023
636P.pdf
Combination Therapy of Envafolimab and Suvemcitug with chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): Results from a Phase II Clinical Trial
Presentation Number：1467P
Speakers ：Chunjiao Wu (Changchun, China)
Onsite Poster display date：Monday, 23 October 2023
1467P.pdf
SIM0235 （TNFR2 mAb）：1 poster
SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): preliminary results from an on-going first-in-human phase I trial in China
Presentation Number：696P
Speakers：Furong Liu (Guangzhou, China)
Onsite Poster display date：Monday, 23 October 2023
696P.pdf
SIM0272 （PRMT5 inhibitor，product code：SCR-6920）：1 poster
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of SCR-6920, a Protein Arginine Methyltransferase 5(PRMT5) Inhibitor, in Patients with Advanced Malignant Tumors
Presentation Number：675P
Speakers：Jinming Yu (Jinan, China)
Onsite Poster display date：Monday, 23 October 2023
675P.pdf